Journal of Health Care and Prevention

Абстрактный

Membrane Lipid Replacement for Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms in Patients with Peripheral Pain: Case Reports

Garth L. Nicolson and Paul Breeding

A preliminary case study was initiated to determine if oral wafers containing a combination of membrane glycerolphospholipids (4-6 g per day) could reduce self-reported peripheral and widespread pain, fatigue, and gastrointestinal symptoms in patients. The first patient was a 51- year-old male veteran who complained of joint and muscle pain, disabling chronic fatigue, nausea, gastrointestinal symptoms (stomach pain, diarrhoea, bloating), intermittent fever, sleep problems, headaches and short-term memory impairments. He had undergone various treatments for post traumatic stress disorder without resolution of his condition. He was placed on 4.8 g per day oral glycerolphospholipids, and within one week reported improvements in pain, fatigue and gastrointestinal symptoms. These gains have been maintained as long as he continues taking the oral glycerolphospholipids. The second patient was a 53-year-old female veteran with sharp stabbing pain and electrical shocks, tingling and numbness in her legs and feet with headaches, fatigue and sleep problems. After 5 months on 2 g per day oral glycerol- phospholipids with slow resolution of her symptoms, she switched to 6 g per day oral glycerolphospholipids with dramatic improvements in peripheral pain, tingling and numbness. Her pain, headaches, fatigue and sleep problems have largely resolved as long as she continues on the oral glycerolphospholipids at a dose of 6 g per day. The third patient was a 68-year-old victim of a point-blank shotgun wound to the abdomen who sustained extensive damage to her large and small bowel that required partial resection in 1978. She suffered for decades from severe, chronic pain, fatigue, diarrhoea and gastrointestinal symptoms that were unresolved with various treatments. Before presentation she discontinued narcotic pain control, and after examination she received myofascial trigger point therapy with spinal manipulation. She was placed on approximately 5 g per day oral glycerolphospholipids. Within 3 weeks she regained control over her bowel movements and her pain and fatigue levels had improved substantially. Patients that have continued taking the oral glycerolphospholipids have not regressed in the severity of their pain, fatigue and gastrointestinal symptoms.